Reported 2 days ago
Eli Lilly has witnessed significant revenue growth due to its successful weight loss drugs, with stocks soaring 170% over three years despite a recent 12% decline. Analysts predict the weight loss drug market could reach $100 billion in five years, with Lilly developing promising new candidates like orforglipron and retatrutide. Although the stock is currently trading at a high valuation, its leadership in the weight loss sector, along with stable revenue from established medicines, makes it a favorable buy during this dip.
Source: YAHOO